Kamada Analyst Ratings
H.C. Wainwright Maintains Kamada(KMDA.US) With Buy Rating, Maintains Target Price $11
Kamada's Promising Growth Potential Backed by Phase 3 InnovAATe Trial and Strong Market Position Justifies Buy Rating
Stifel Maintains Kamada(KMDA.US) With Buy Rating, Raises Target Price to $20
Kamada Analyst Ratings
H.C. Wainwright Maintains Kamada(KMDA.US) With Buy Rating, Maintains Target Price $11
Buy Rating Affirmed for Kamada on Strong Clinical and Financial Performance
Stifel Initiates Coverage On Kamada With Buy Rating, Announces Price Target of $18
Kamada Analyst Ratings
Kamada Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target
Buy Rating Affirmed for Kamada on Accelerated Trial Prospects and Strong Financial Performance
Kamada Analyst Ratings
Kamada Analyst Ratings
Promising Revenue Growth and Diverse Portfolio Drive Strong Buy Rating for Kamada: An Analysis by Andrew Fein
Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL), Kamada (KMDA) and Mediwound (MDWD)
HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target
Kamada Analyst Ratings
H.C. Wainwright Remains a Buy on Kamada (KMDA)
HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target